EFTR - eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

• eFFECTOR Therapeutics ( NASDAQ: EFTR ) on Wednesday said it had dosed the first patient in the second cohort of its phase 1b clinical trial of its investigational cancer therapy zotatifin for the potential treatment of COVID-19.
• The early-stage trial is assessing the safety and antiviral activity of a single dose of zotatifin in patients with mild to moderate COVID, and is being conducted in collaboration with the University of California, San Francisco, EFTR said in a statement .
• The trial is being conducted using a $5M cooperative agreement sponsored by the government-led Defense Advanced Research Projects Agency.
• The dosing of the first patient in the second cohort follows a positive recommendation of an independent data safety board which reviewed data from the first dose cohort, EFTR said.
• EFTR stock marginally higher in morning trading.

For further details see: